Dr Reddy’s Laboratories to introduce biosimilars in developed markets

07 Jul 2012 Evaluate

Dr Reddy’s Laboratories, country’s pharma major has decided to introduce its biosimilars in developed markets. biosimilars are used to treat patients suffering from cancer at a price that is significantly more affordable than the corresponding innovator drugs. During 2011-12, the company’s global biosimilars business earned $26 million revenue reporting 25% year-on-year growth.

Recently, the company entered into a partnership with Merck Serono, a division of Germany-based Merck KGaA, to co-develop biosimilar compounds. The collaboration was to concentrate on monoclonal antibodies (MAbs) in the oncology segment besides, manufacturing and commercialization of the compounds.

Dr. Reddys Lab Share Price

1267.50 1.55 (0.12%)
31-Dec-2025 12:03 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.00
Dr. Reddys Lab 1267.50
Cipla 1500.80
Zydus Lifesciences 912.35
Lupin 2102.60
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×